2019 | |
Roerden, M, Walz, JS, Müller, MR, Sökler, M, Federmann, B, Kanz, L, Bethge, W, Vogel, W (2019). The role of autologous stem cell transplantation in peripheral T cell lymphoma: a long-term follow-up single-center experience. J Cancer Res Clin Oncol [in press]. | |
Bauer, J, Nelde, A, Bilich, T, Walz, JS (2019). Antigen Targets for the Development of Immunotherapies in Leukemia. Int J Mol Sci. 2019 Mar 20;20(6). | |
Bilich, T*, Nelde, A*, Bichmann, L, Roerden, M, Salih, HR, Kowalewski, DJ, Schuster, H, Tsou, CC, Marcu, A, Neidert, MC, Lübke, M, Rieth, J, Schemionek, M, Brümmendorf, TH, Vucinic, V, Niederwieser, D, Bauer, J, Märklin, M, Peper, JK, Klein, R, Kohlbacher, O, Kanz, L, Rammensee, HG, Stevanović, S, Walz, JS (2019). The HLA ligandome landscape of chronic myeloid leukemia delineates novel T-cell epitopes for immunotherapy. Blood 133(6):550-565. | |
2018 | |
Kuželová, K, Brodská, B, Schetelig, J, Röllig, C, Ráčil, Z, Walz, JS, Helbig, G, Fuchs, O, Vraná, M, Pecherková, P, Šálek, C, Mayer, J (2018). Association of HLA class I type with prevalence and outcome of patients with acute myeloid leukemia and mutated nucleophosmin.. PLoS One 13(12):e0204290. | |
Walz, JS, Kowalewski, DJ, Backert, L, Nelde, A, Kohlbacher, O, Weide, B, Kanz, L, Salih, HR, Rammensee, HG, Stevanović, S (2018). Favorable immune signature in CLL patients, defined by antigen-specific T-cell responses, might prevent second skin cancers. Leuk Lymphoma 59(8):1949-1958. | |
Neidert, MC, Kowalewski, DJ, Silginer, M, Kapolou, K, Backert, L, Freudenmann, LK, Peper, JK, Marcu, A, Wang, SS, Walz, JS, Wolpert, F, Rammensee, HG, Henschler, R, Lamszus, K, Westphal, M, Roth, P, Regli, L, Stevanović, S, Weller, M, Eisele, G (2018). The natural HLA ligandome of glioblastoma stem-like cells: antigen discovery for T cell-based immunotherapy. Acta Neuropathol 135(6):923-938. | |
Nelde, A, Kowalewski, DJ, Backert, L, Schuster, H, Werner, JO, Klein, R, Kohlbacher, O, Kanz, L, Salih, HR, Rammensee, HG, Stevanović, S, Walz, JS (2018). HLA ligandome analysis of primary chronic lymphocytic leukemia (CLL) cells under lenalidomide treatment confirms the suitability of lenalidomide for combination with T-cell-based immunotherapy. Oncoimmunology 7(4):e1316438. | |
2017 | |
Maurer, S, Kropp, KN, Klein, G, Steinle, A, Haen, SP, Walz, JS, Hinterleitner, C, Märklin, M, Kopp, HG, Salih, HR (2017). Platelet-mediated shedding of NKG2D ligands impairs NK cell immune-surveillance of tumor cells. Oncoimmunology 7(2):e1364827. | |
Schuster, H, Peper, JK, Bösmüller, HC, Röhle, K, Backert, L, Bilich, T, Ney, B, Löffler, MW, Kowalewski, DJ, Trautwein, N, Rabsteyn, A, Engler, T, Braun, S, Haen, SP, Walz, JS, Schmid-Horch, B, Brucker, SY, Wallwiener, D, Kohlbacher, O, Fend, F, Rammensee, HG, Stevanović, S, Staebler, A, Wagner, P (2017). The immunopeptidomic landscape of ovarian carcinomas. Proc Natl Acad Sci U S A 114(46):E9942-E9951. | |
Heidenreich, F, Rücker-Braun, E, Walz, JS, Eugster, A, Kühn, D, Dietz, S, Nelde, A, Tunger, A, Wehner, R, Link, CS, Middeke, JM, Stölzel, F, Tonn, T, Stevanovic, S, Rammensee, HG, Bonifacio, E, Bachmann, M, Zeis, M, Ehninger, G, Bornhäuser, M, Schetelig, J, Schmitz, M (2017). Mass spectrometry-based identification of a naturally presented receptor tyrosine kinase-like orphan receptor 1-derived epitope recognized by CD8+ cytotoxic T cells. Haematologica 102(11):e460-e464. | |
Liu, X, Pichulik, T, Wolz, OO, Dang, TM, Stutz, A, Dillen, C, Delmiro Garcia, M, Kraus, H, Dickhöfer, S, Daiber, E, Münzenmayer, L, Wahl, S, Rieber, N, Kümmerle-Deschner, J, Yazdi, A, Franz-Wachtel, M, Macek, B, Radsak, M, Vogel, S, Schulte, B, Walz, JS, Hartl, D, Latz, E, Stilgenbauer, S, Grimbacher, B, Miller, L, Brunner, C, Wolz, C, Weber, ANR (2017). Human NACHT, LRR, and PYD domain-containing protein 3 (NLRP3) inflammasome activity is regulated by and potentially targetable through Bruton tyrosine kinase. J Allergy Clin Immunol 140(4):1054-1067.e10. | |
Backert, L, Kowalewski, DJ, Walz, S, Schuster, H, Berlin, C, Neidert, MC, Schmeionek, M, Brümmendorf, TH, Vucinic, V, Niederwieser, D, Kanz, L, Salih, HR, Kohlbacher, O, Weisel, K, Rammensee, HG, Stevanović, S, Walz, JS (2017). A meta-analysis of HLA peptidome composition in different hematological entities: Entity-specific dividing lines and “pan-leukemia” antigens. Oncotarget 8(27): 43915–43924. | |
2016 | |
Nelde, A, Stickel, JS, Kowalewski, DJ, Schuster, H, Wolz, O, Peper, JK, Gloria, YC, Langerak, AW, Muggen, AF, Claus, R, Bonzheim, I, Fend, F, Salih, HR, Kanz, L, Rammensee, H-G, Stevanović, S, Weber, ANR (2016). HLA class I-restricted MYD88 L265P-derived peptides as specific targets for lymphoma immunotherapy. OncoImmunology 2017;6(3):e1219825. | |
Kowalewski, DJ, Walz S, Backert L, Schuster H, Kohlbacher O, Weisel K, Rittig SM, Kanz L, Salih HR, Rammensee, HG, Stevanovic, S and Stickel, JS (2016). Carfilzomib alters the HLA-presented peptidome of myeloma cells and impairs presentation of peptides with aromatic C-termini. Blood Cancer J 6: e411. | |
Werner JO*, Stickel JS*, M, Droppa, P, Krumm, MR, Müller, L, Kanz, F, Kreth (2016) Pericardial effusion as first manifestation of NSCLC. Ann Hematol Oncol. [In press]. | |
2015 | |
Walz, S*, Stickel, JS*, Kowalewski, DJ, Schuster, H, Weisel, K, Backert, L, Kahn, S, Nelde, A, Stroh, T, Handel, M, Kohlbacher, O, Kanz, L, Salih, HR, Rammensee, HG, Stevanović, S (2015) The antigenic landscape of multiple myeloma: mass spectrometry (re)defines targets for T-cell based immunotherapy. Blood. 2015 Sep 3;126(10):1203-13. | |
Kowalewski, DJ, Stevanovic, S, Rammensee, HG, Stickel, JS (2015) Anti-leukemia T cell responses in CLL – We don’t need no aberration. Oncoimmunology. 2015 Mar 16;4(7). | |
Kowalewski, DJ, Schuster, H, Backert, L, Berlin, C, Kahn, S, Kanz, L, Salih, HR, Rammensee, HG, Stevanovic, S, Stickel, JS (2015) HLA ligandome analysis identifies the underlying specificities of spontaneous anti-leukemia immune responses in CLL. Proc Natl Acad Sci U S A. 2015 Jan 13;112(2):E166-75. | |
Berlin, C, Kowalewski, DJ, Schuster, H, Mirza, N, Walz, S, Handel, M, Schmid-Horch, B, Salih, HR, Kanz, L, Rammensee, HG, Stevanovic, S, & Stickel, JS (2015) Mapping the HLA ligandome landscape of acute myeloid leukemia: a targeted approach toward peptide-based immunotherapy. Leukemia. 2015 Mar;29(3):647-59. | |
2013 | |
Stickel, JS, Mayer, F, Vollmer, JP, Zurn, CS, Gawaz, M, Kanz, L, & Bauer, A (2013) Ventricular thrombus and thrombocytopenia as first presentation of anaplastic thyroid carcinoma. J Clin Oncol 31(12):e194-196. | |
Seizer, P, Klingel, K, Stickel, J, Dorn, C, Horger, M, Kandolf, R, Bigalke, B, May, AE, Gawaz, M, & Schreieck, J (2013) Left ventricular site-directed biopsy guided by left ventricular voltage mapping: a proof of principle. Int J Cardiol 168(3):3113-3114. | |
2011 | |
Bolla, D, Wiedemann, N, Ohlschlegel, C, Schoning, A, Stickel, J, Thurlimann, B, & Hornung, R (2011) Pseudoangiomatous stromal hyperplasia of breast in man: a case report. The breast journal 17(3):311-312. | |
Stickel, JS, Stickel, N, Hennenlotter, J, Klingel, K, Stenzl, A, Rammensee, HG, & Stevanovic, S (2011) Quantification of HLA class I molecules on renal cell carcinoma using Edman degradation. BMC Urol 11:1. | |
Stickel, JS (2011) Tumorantigene des Nierenzellkarzinoms, Südwest-deutscher Verlag für Hochschulschriften, Book p 224 | |
2009 | |
Stickel, JS, Weinzierl, AO, Hillen, N, Drews, O, Schuler, MM, Hennenlotter, J, Wernet, D, Muller, CA, Stenzl, A, Rammensee, HG, & Stevanovic, S (2009) HLA ligand profiles of primary renal cell carcinoma maintained in metastases. Cancer Immunol Immunother 58(9):1407-1417. |
* These authors contributed equally to this work